Respiratory Drugs Market Size, Share, Growth and Forecast, 2025-2035

Asthma and COPD keep inhaled therapy at the center

The global respiratory drugs market was valued at USD 18.48 billion in 2025 and is projected to increase from USD 19.49 billion in 2026 to USD 31.48 billion by 2035, registering a CAGR of 5.47% during 2026–2035. Demand comes from hundreds of millions of people with asthma and chronic obstructive pulmonary disease who use inhalers every day, together with new biologic medicines for patients whose disease stays uncontrolled. North America held the largest regional share, 42.0% in 2025, because the United States pays high prices for branded inhalers and biologics. Asia Pacific is the fastest-growing region at 6.65% a year, as China and India diagnose more patients and widen insurance coverage. The treatment picture changed in September 2024, when U.S. regulators approved the first biologic for COPD. As a result, injectable therapy now reaches a disease that relied almost entirely on inhaled medicines.

Which lung disease medicines does this analysis cover?

The analysis counts short-acting and long-acting beta2-agonists, inhaled corticosteroids, anticholinergics, antihistamines and other medicines, including biologics and PDE inhibitors, used to treat asthma, chronic bronchitis, COPD and pleural effusion. Values are based on manufacturer selling prices across inhaled, oral and injectable forms.

Inhaler hardware sold without a medicine, vaccines, oxygen and hospital services sit outside the scope of this analysis. The value chain runs from active ingredient and device component makers through branded and generic manufacturers and wholesalers to hospital, retail and online pharmacies that dispense medicines to patients.

Inhaled corticosteroids lead while biologics gain ground

Why do inhaled corticosteroids lead drug class spending?

Based on drug class, the market is categorized into short-acting beta2-agonists, long-acting beta2-agonists, inhaled corticosteroids, anticholinergics, antihistamines and others. Inhaled Corticosteroids led with a 26.0% share of 2025 value, because guidelines place them at the base of daily asthma control. Others, which include biologics and PDE inhibitors, grow fastest at 6.98% a year, as new approvals reach patients with severe disease.

Which disease accounts for most treatment value?

Based on disease type, the market is categorized into asthma, chronic bronchitis, chronic obstructive pulmonary disease and pleural effusion. Asthma led with a 44.0% share of 2025 value, because it affects children and adults who often need daily controller inhalers. Chronic Obstructive Pulmonary Disease grows fastest at 5.94% a year, as new biologics and a first-in-class maintenance medicine widen options for patients.

Why does inhalation remain the main route?

Based on route of administration, the market is categorized into inhalation, oral and parenteral. Inhalation led with a 68.0% share of 2025 value, because inhalers and nebulized medicines deliver treatment directly to the lungs. Parenteral medicines grow fastest at 6.97% a year, as injectable biologics for severe asthma and COPD reach more patients through specialist clinics and home injection programs.

Where do patients fill most prescriptions?

Based on distribution channel, the market is categorized into hospital pharmacies, retail pharmacies and online pharmacies. Retail Pharmacies led with a 52.0% share of 2025 value, because most controller and rescue inhalers are refilled monthly near home. Online Pharmacies grow fastest at 7.05% a year, as mail delivery, digital prescriptions and automatic refill programs spread among patients who need controller inhalers every month.

Asthma burden and new COPD biologics lift treatment value

How does the global asthma burden sustain demand?

The global asthma burden sustains demand, because most patients need controller or rescue medicine for many years. The World Health Organization estimates that asthma affected 363 million people in 2023 and caused 442,000 deaths. The same source notes that most asthma deaths occur in low- and lower-middle-income countries, where under-diagnosis and under-treatment remain common. Inhalers are the most common treatment, and many people use them every day. As a result, asthma held 44.0% of 2025 disease value, the largest share. In turn, wider diagnosis in poorer countries adds new long-term users of inhaled medicines, since each newly diagnosed child or adult may need treatment for decades.

Why do new COPD biologics raise spending per patient?

New COPD biologics raise spending per patient, because they treat people whose disease stays uncontrolled on inhalers. In September 2024, Sanofi announced U.S. approval of Dupixent as the first biologic for adults with inadequately controlled COPD and an eosinophilic phenotype. The company estimated that about 300,000 U.S. adults fit this profile and that about half of COPD patients still have flare-ups despite triple inhaled therapy. In May 2025, GSK received U.S. approval of Nucala for a similar COPD population. As a result, COPD grows at 5.94% a year, the fastest disease type, and specialist lung clinics are adding capacity to start and monitor biologic treatment.

Download Free Sample

How do longer-acting biologics expand severe asthma care?

Longer-acting biologics expand severe asthma care, because fewer injections make treatment easier for patients and clinics. In December 2025, GSK received U.S. approval of Exdensur, an add-on treatment for severe eosinophilic asthma in people aged 12 and older given twice a year. GSK also stated in May 2025 that nearly 70% of U.S. COPD patients poorly controlled on triple therapy have blood eosinophil counts of at least 150 cells per microliter. This large pool of eligible patients widens the use of eosinophil-targeted medicines in both asthma and COPD clinics. As a result, parenteral medicines grow at 6.97% a year, faster than inhaled or oral routes.

Why do price caps support steady inhaler use?

Price caps support steady inhaler use, because patients who pay less are more likely to refill controller medicines each month. Boehringer Ingelheim and AstraZeneca capped out-of-pocket costs for eligible U.S. patients at $35 a month from June 1, 2024, and GSK committed to a similar cap by January 2025. The Centers for Disease Control and Prevention reports that 27.8 million Americans, or 8.4% of the population, had current asthma in 2023. As a result, retail pharmacies held 52.0% of 2025 channel value, the largest share, because most capped inhalers are refilled close to home every month at community pharmacy counters.

Greener propellants, deals and generics reshape supply

How is the shift to low-carbon propellants reshaping inhalers?

The shift to low-carbon propellants is reshaping inhalers, because current metered-dose inhalers use gases with high global warming potential. In May 2025, AstraZeneca announced U.K. approval of Trixeo Aerosphere with the HFO-1234ze(E) propellant, which has 99.9% lower global warming potential than current propellants. The company said applications were under review in Europe, China and other countries. AstraZeneca also aims to move its wider pressurized inhaler portfolio to the new propellant by 2030. As a result, other inhaler makers face pressure to reformulate products before regulators tighten limits on older gases, which could raise development and testing costs across the industry.

Why are large companies rising as buyers of COPD innovation?

Large companies are rising as buyers of COPD innovation, because few new maintenance mechanisms reached the market in recent decades. In June 2024, Verona Pharma announced U.S. approval of Ohtuvayre, a first-in-class dual inhibitor of PDE3 and PDE4 delivered through a standard jet nebulizer. In October 2025, Merck completed its acquisition of Verona Pharma for $107 per American depositary share, a deal worth about $10 billion. Verona had cited more than 390 million people living with COPD worldwide. As a result, large companies now compete for nebulized and inhaled COPD assets, and smaller developers with late-stage lung medicines attract strong buyer interest.

Download Free Sample

Can generic inhalers open wider access in the United States?

Generic makers have a clear opening in complex inhalers, because many branded dry powder products have lost patent protection. In July 2026, Cipla received U.S. approval for a generic version of Advair Diskus in three strengths, 100/50, 250/50 and 500/50 micrograms, for asthma and COPD. It was the first dry powder inhaler approval from the company's U.S. manufacturing network in New York. Lower-priced copies widen access for uninsured patients and reduce costs for public and private payers. As a result, online pharmacies, which grow at 7.05% a year, can offer generic asthma treatment at lower cost to patients who pay cash.

Where can new mechanisms beyond inhalers add value?

New mechanisms beyond inhalers give companies room to add value, because several lung diseases still lack effective oral medicines. In October 2025, U.S. regulators approved Boehringer Ingelheim's Jascayd for idiopathic pulmonary fibrosis, the first novel therapy for the disease in more than 10 years. In its main trial, lung capacity fell by 106 milliliters at the higher dose over 52 weeks, compared with 170 milliliters on placebo. As a result, other drug classes, which include biologics and PDE inhibitors, grow at 6.98% a year, the fastest pace of any class, as companies extend research from asthma and COPD into fibrosis and other rare lung diseases.

Price erosion, inhaler technique and access gaps weigh

How does generic entry erode branded inhaler value?

Generic entry erodes branded inhaler value, because payers switch patients to lower-priced copies once they become available. Approvals of generic dry powder and metered-dose inhalers reduce prices for older combination products. Branded makers then lose volume in retail pharmacies, where most refills happen, and often cut list prices to keep formulary positions. As a result, originators shift investment toward biologics, new mechanisms and smart inhalers that can justify higher prices.

Why does poor inhaler technique limit treatment results?

Poor inhaler technique limits treatment results, because medicine that does not reach the lungs cannot control symptoms. The World Health Organization notes that using an inhaler can be difficult, especially for children and during emergencies. Many patients then rely on rescue inhalers instead of daily controllers. In turn, clinicians recommend spacers, nebulizers and regular training at each visit, which raises the cost of care for clinics and health systems with limited staff time.

How do access gaps keep patients undertreated?

Access gaps keep patients undertreated, because inhaled medicines remain costly or unavailable in many poorer countries. Most asthma deaths occur in low- and lower-middle-income countries, where diagnosis and treatment are often missed. Patients there often receive oral medicines or short-acting relievers rather than controller inhalers. As a result, value growth in these markets trails the growth in diagnosed patients, even as public programs expand essential medicine lists to include more inhalers.

Why do biologic prices face payer controls?

Biologic prices face payer controls, because each patient may cost much more a year than inhaled therapy alone. Insurers require blood eosinophil tests, records of past flare-ups and failed inhaler treatment before they cover a biologic. These steps delay treatment for some eligible patients by several weeks or months, and some patients give up on approval. In turn, companies invest in evidence that shows fewer hospital visits for COPD treatment with biologics.

North America leads as Asia Pacific expands fastest

Why does North America hold the largest regional share?

North America held a 42.0% share of 2025 value and grows at 5.05% a year through 2035. The United States drives this position, because branded inhalers and biologics sell at high prices and insurance covers most patients. U.S. approvals of Dupixent and Nucala for COPD and Exdensur for asthma add new spending. Generic inhaler entry and $35 monthly caps, however, hold down price growth for older inhalers.

Why do China and India drive Asia Pacific growth?

Asia Pacific held a 22.0% share of 2025 value and is the fastest-growing region at 6.65% a year. China and India have large populations exposed to tobacco smoke and air pollution, and both countries are diagnosing more patients. Local generic makers such as Cipla Ltd supply low-cost inhalers across the region. AstraZeneca has also filed its low-carbon inhaler in China, which points to future product changes.

Download Free Sample

What shapes demand across Europe?

Europe held a 26.0% share of 2025 value and grows at 4.85% a year, the slowest pace of the five regions. Germany, France, Italy and the United Kingdom account for much of the spending, and national health systems negotiate prices firmly. The region is also leading the move to low-carbon inhaler propellants. However, generic competition keeps value growth below the global average.

Where is Latin America adding demand?

Latin America held a 6.0% share of 2025 value and grows at 5.95% a year through 2035. Brazil and Mexico lead regional spending, because asthma is common and public health systems are widening inhaler access. However, biologic use remains limited by cost and by the small number of specialist clinics.

What limits growth in the Middle East and Africa?

The Middle East and Africa held a 4.0% share of 2025 value and grows at 6.15% a year through 2035. Gulf states fund branded inhalers and biologics, while much of Africa still lacks steady supplies of controller medicines.

Download Free Sample

Biologic approvals and inhaler deals since 2024

Biologics, PDE inhibitors and low-carbon inhalers advance

• Eosinophil-targeted biologics block inflammation pathways in severe asthma and COPD, which reduces flare-ups in patients that inhalers fail to control.
• Ultra-long-acting biologics need only two doses a year, which lowers the treatment burden for patients and clinics.
• Dual PDE3 and PDE4 inhibitors combine airway opening and anti-inflammatory effects in one nebulized medicine, which helps patients who struggle with handheld inhalers.
• Low-carbon propellants cut the climate effect of metered-dose inhalers by more than 99%, which helps inhalers meet tighter rules on fluorinated gases.
• Complex generic inhalers match branded dry powder products in dose and delivery, which widens access at lower cost.

Inhaler leaders and biologic makers compete for patients

Competition splits between large inhaler franchises, biologic makers and generic suppliers. GlaxoSmithKline Plc, AstraZeneca Plc and Boehringer Ingelheim International GmbH hold broad inhaled portfolios, and all three adopted $35 monthly caps for eligible U.S. patients in 2024 and 2025. GSK added COPD and asthma biologic approvals in 2025, while Sanofi gained the first COPD biologic approval with Regeneron in 2024. Merck & Co., Inc. entered COPD maintenance through its 2025 Verona Pharma acquisition. Novartis AG, Roche, Pfizer Inc., AbbVie Inc. and Vertex Pharmaceuticals Incorporated compete in allergy, immunology, anti-infective and cystic fibrosis care. Teva Pharmaceutical Industries Ltd. and Cipla Ltd lead in generic inhalers. As a result, buyers weigh clinical evidence, device ease and price.

Companies profiled and their roles in this market

Biologics and COPD care set the growth pace

Credence Research's view is that biologics and new COPD medicines will set the pace of growth through 2035, because they reach patients that inhalers alone fail to control. The overall market grows at 5.47% a year, supported by a large asthma burden, rising COPD diagnosis and wider insurance coverage in Asia. Parenteral and online channels grow faster than inhaled retail sales. Companies that combine strong clinical data, easy devices and low-carbon inhalers will gain the most share, while generic entry will keep pressure on older brands.

How Credence Research sized lung disease medicines

The report uses 2025 as the base year and 2026 to 2035 as the forecast period. Market values come from the Credence Research model, which builds spending by drug class, disease type, route of administration, distribution channel and region. Regional and segment splits are Credence Research estimates informed by World Health Organization data, U.S. public health statistics, regulator decisions and company press releases. No primary interviews or surveys were used in preparing this edition.

Asthma and COPD medicine outlook to 2035

By 2035, the respiratory drugs market is projected to reach USD 31.48 billion, with growth led by biologics, new COPD maintenance medicines and low-carbon inhalers. Inhaled corticosteroids will remain the largest drug class, as daily controller use continues for asthma. North America keeps the highest spending, while Asia Pacific adds the most new patients. Generic inhalers will widen access but lower prices for older brands. As a result, advantage will depend on clinical evidence, device ease and access programs that keep patients on treatment.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.